# CADL catalysts: Candel Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cadl/catalysts

> Candel Therapeutics, Inc. (CADL) has 5 upcoming catalysts. The next is the aglatimagene besadenovec NDA/BLA submission, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CADL?

Candel Therapeutics, Inc. (CADL) has 5 upcoming catalysts. The next is the aglatimagene besadenovec NDA/BLA submission, Q1 2027. Press release filed with the SEC (EX-99): "Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will support the preparation and submission of a BLA for CAN-2409 in prostate cancer, as well as fund its current operating plan into Q1 2027." [Calendar and source filings](https://sec-api.dev/companies/cadl/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0000950170-25-004581, https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/cadl-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-09-10. Cite: https://sec-api.dev/companies/cadl/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Candel Therapeutics, Inc. |
| Ticker | CADL (Nasdaq) |
| SEC CIK | 1841387 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/cadl |

## Cash runway

Cash $203.1M as of 2026-09-30; quarterly burn $23.1M; about 26.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-458380).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2024 | [Aglatimagene besadenovec topline data readout](https://sec-api.dev/pdufa/aglatimagene-besadenovec) | CADL |  | scheduled | "On track for topline progression-free survival data from the phase 2b randomized controlled clinical trial of CAN-2409 in the active surveillance population with localized low/intermediate risk prostate cancer, expected in Q4 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-ex99_1.htm)) |
| November 14, 2024 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-ex99_1.htm)) |
| Dec 2024 | [Aglatimagene topline data readout](https://sec-api.dev/pdufa/aglatimagene) | CADL |  | completed, met | "We reported positive topline data on this trial in December 2024, demonstrating that aglatimagene in combination with SoC radiation+/- short course ADT was able to significantly improve DFS in early prostate cancer compared with SoC radiation+/- short course of ADT alone, with a statistically significant improvement of DFS of 30% (hazard ratio 0.7)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/cadl-20251231.htm)) |
| December 11, 2024 | [Aglatimagene besadenovec topline data readout](https://sec-api.dev/pdufa/aglatimagene-besadenovec) | CADL |  | completed, positive | "On December 11, 2024, the Company announced positive topline data from its phase 3 clinical trial in the United States conducted under a SPA with the FDA evaluating patients with newly diagnosed, localized prostate cancer who have an intermediate-to-high risk for progression." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312524274870/d901922d8k.htm)) |
| March 13, 2025 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017025038757/cadl-ex99_1.htm)) |
| May 13, 2025 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017025069826/cadl-ex99_1.htm)) |
| August 14, 2025 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017025108448/cadl-ex99_1.htm)) |
| October 14, 2025 | [Linoserpaturev interim data readout](https://sec-api.dev/pdufa/linoserpaturev) | CADL |  | completed, positive | "On October 14, 2025, the Company announced positive interim data from its ongoing phase 1b clinical trial of CAN-3110 in recurrent glioblastoma." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312525238254/cadl-20251014.htm)) |
| November 13, 2025 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm)) |
| December 2025 | [Aglatimagene besadenovec primary completion](https://sec-api.dev/pdufa/aglatimagene-besadenovec) | CADL | Borderline Resectable Pancreatic Adenocarcinoma | delayed | "NCT02446093 (Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma): Overall Status UNKNOWN; Phase PHASE2; Primary Completion 2025-12 (ESTIMATED); Lead Sponsor Candel Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02446093)) |
| February 19, 2026 | [Aglatimagene FDA approval](https://sec-api.dev/pdufa/aglatimagene) | CADL |  | completed, approved | "On February 19, 2026, Candel announced a $100 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of aglatimagene in localized, intermediate- to high-risk, prostate cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/cadl-ex99_1.htm)) |
| March 12, 2026 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/cadl-ex99_1.htm)) |
| Q2 2026 | [Aglatimagene besadenovec trial start](https://sec-api.dev/pdufa/aglatimagene-besadenovec) | CADL | metastatic, non-squamous, non-small cell lung cancer | scheduled | "Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm)) |
| May 14, 2026 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/cadl-ex99_1.htm)) |
| Jun 2026 | [Aglatimagene trial start](https://sec-api.dev/pdufa/aglatimagene) | CADL | progressive, metastatic, non-squamous NSCLC despite ICI treatment | scheduled | "The Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene in patients with metastatic, non-squamous, NSCLC, and progressive disease despite ICI treatment in June 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/cadl-ex99_1.htm)) |
| August 13, 2026 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm)) |
| Q4 2026 | [Aglatimagene NDA/BLA submission](https://sec-api.dev/pdufa/aglatimagene) | CADL |  | scheduled | ""This quarter reflects meaningful execution across the company as we advance aglatimagene toward a planned BLA submission in the fourth quarter of 2026 and continue to build the foundation for a potential U.S. commercial launch in localized prostate cancer," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm)) |
| November 12, 2026 | [Aglatimagene trial start](https://sec-api.dev/pdufa/aglatimagene) | CADL | metastatic non-squamous NSCLC | completed | "As previously announced, the Company initiated the first clinical trial site of the global pivotal phase 3 clinical trial (AURORA) (NCT07660094), which is evaluating aglatimagene plus valacyclovir in combination with continued pembrolizumab in patients with metastatic non-squamous NSCLC whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526458316/cadl-ex99_1.htm)) |
| November 12, 2026 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526458316/cadl-ex99_1.htm)) |
| Q1 2027 | [Aglatimagene besadenovec NDA/BLA submission](https://sec-api.dev/pdufa/aglatimagene-besadenovec) | CADL |  | scheduled | "Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will support the preparation and submission of a BLA for CAN-2409 in prostate cancer, as well as fund its current operating plan into Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/cadl-ex99_1.htm)) |
| Q1 2027 | [Aglatimagene besadenovec trial start](https://sec-api.dev/pdufa/aglatimagene-besadenovec) | CADL |  | scheduled | "Cash and cash equivalents of $87.0M, as of September 30, 2025, plus the upfront proceeds from the Trinity Capital debt facility, strengthens the Company's financial position to fund initiation of potentially registrational phase 3 trial of CAN-2409 in NSCLC and other planned operations into Q1 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm)) |
| February 2027 | [Aglatimagene besadenovec + valacyclovir primary completion](https://sec-api.dev/pdufa/aglatimagene-besadenovec-valacyclovir) | CADL | Prostate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma) | scheduled | "NCT07332000 (A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Candel Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07332000)) |
| Feb to May 2027 | [Aglatimagene besadenovec + valacyclovir topline data readout](https://sec-api.dev/pdufa/aglatimagene-besadenovec-valacyclovir) | CADL | Prostate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma) | scheduled | "NCT07332000 (A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Candel Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07332000)) |
| mid-2027 | [Aglatimagene NDA/BLA submission](https://sec-api.dev/pdufa/aglatimagene) | CADL |  | scheduled | "Due to timelines associated with certain assay refinement, the Company currently plans to submit this BLA in the middle of 2027 pending the result of that dialogue." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526458316/cadl-ex99_1.htm)) |

## Drugs

- [Aglatimagene](https://sec-api.dev/pdufa/aglatimagene): progressive, metastatic, non-squamous nsclc despite ici treatment, metastatic, non-squamous nsclc progressing, progressive, metastatic, nsclc despite ici treatment, in q2 2026, metastatic, non-squamous, nsclc and progressive disease despite ici treatment in q2 2026, metastatic non-squamous nsclc
- [Aglatimagene besadenovec](https://sec-api.dev/pdufa/aglatimagene-besadenovec): progressive, metastatic, non-squamous nsclc despite ici treatment, metastatic, non-squamous, non-small cell lung cancer, Borderline Resectable Pancreatic Adenocarcinoma
- [Aglatimagene besadenovec + valacyclovir](https://sec-api.dev/pdufa/aglatimagene-besadenovec-valacyclovir): Prostate Cancer Patients Treated by Radiotherapy
- [Linoserpaturev](https://sec-api.dev/pdufa/linoserpaturev): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cadl/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CADL catalysts: Candel Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cadl/catalysts

```bibtex
@misc{secapidev_companies_cadl_catalysts_20261116,
  title        = {CADL catalysts: Candel Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cadl/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cadl_catalysts_20261116","title":"CADL catalysts: Candel Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cadl/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
